Pharmacokinetic and phase I trial of intraperitoneal carboplatin and cyclosporine in refractory ovarian cancer patients

Journal of Clinical Oncology

Volumn 15, Issue 5, 1997, Pages 1945-1952

  Chambers, S K ^a   Chambers, J T ^a   Davis, C A ^a   Kohorn, E I ^a   Schwartz, P E ^a   Lorber, M I ^a   Handschumacher, R E ^a   Pizzorno, G ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLOSPORIN A;

AREA UNDER THE CURVE; ARTICLE; ASCITES; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG HALF LIFE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; INTRAPERITONEAL DRUG ADMINISTRATION; NEUROTOXICITY; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0030994519     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.5.1945     Document Type: Article

References (37)

1. Lum BL, Kaubisch S, Yahanda AM, et al: Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 10:1635-1642, 1992
2. Samuels BL, Mick R, Vogelzang NJ, et al: Modulation of vinblastine resistance with cyclosporine: A phase I study. Clin Pharmacol Ther 54:421-429, 1993
3. Bartlett NL, Lum BL, Fisher GA, et al: Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 12:835-842, 1994
4. Erlichman C, Moore M, Thiessen JJ, et al: Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. Cancer Res 53:4837-4842, 1993
5. Yahanda AM, Adler KM, Fisher GA, et al: Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 10:1624-1634, 1992
6. Sonneveld P, Durie BGM, Lokhorst HM, et al: Modulation of multidrug-resistant multiple myeloma by cyclosporin. Lancet 340:255-259, 1992
7. Kashani-Sabet M, Wang W, Scanlon KJ: Cyclosporin A suppresses cisplatin-induced c-fos gene expression in ovarian carcinoma cells. J Biol Chem 265:11285-11288, 1990
8. Mutch DG, Herzog TJ, Chen CA, et al: The effects of cyclosporin A on the lysis of ovarian cancer cells by cisplatin or Adriamycin. Gynecol Oncol 47:28-33, 1992
9. Stratton JA, DiSaia PJ: Reversal of cisplatinum resistance by cyclosporin A in xenografts of fresh human ovarian carcinoma. Proc Am Assoc Cancer Res 29: 479, 1988 (abstr 1904)
10. Manetta A, Boyle J, Berman ML, et al: Cyclosporin enhancement of cisplatin chemotherapy in patients with refractory gynecologic cancer. Cancer 73:196-199, 1994
11. Morgan RJ, Margolin K, Raschko J, et al: Phase I trial of carboplatin and infusional cyclosporine in advanced malignancy. J Clin Oncol 13:2238-2246, 1995
12. Chambers SK, Davis CA, Kohorn EI, et al: Modulation of platinum sensitivity and resistance by cyclosporin A in refractory ovarian and fallopian tube cancer patients: A phase II study. Clin Cancer Res 2:1693-1698, 1996
13. Chambers SK, Davis CA, Chambers JT, et al: Phase I trial of intravenous carboplatin and cyclosporin A in refractory gynecologic cancer patients. Clin Cancer Res 2:1699-1704, 1996
14. Markman M: Newer techniques in cancer chemotherapy, in Disease-a-Month. Chicago, IL, Year Book Medical, 1984
15. Dedrick RL, Myers CE, Bugay PM, et al: Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 62:1-11, 1978
16. Kahan BD: Individualization of cyclosporine therapy using pharmacokinetic and pharmacodynamic parameters. Transplantation 40:457-476, 1985
17. Wassef R, Cohen Z, Langer B: Pharmacokinetic profiles of cyclosporine in rats. Transplantation 40:489-493, 1985
18. Chambers SK, Hait WN, Kacinski BM, et al: Enhancement of anthracycline growth inhibition in parent and multidrug resistant Chinese hamster ovary cells by cyclosporin A and its analogues. Cancer Res 49:6275-6279, 1989
19. Silbermann MH, Boersma AWM, Janssen ALW, et al: Effects of cyclosporin A and verapamil on the intracellular daunorubicin accumulation in Chinese hamster cells with increasing levels of drug resistance. Int J Cancer 44:722-726, 1989
20. Alberts D, Green S, Hannigan E, et al: Improved efficacy of carboplatin/cyclophosphamide vs cisplatin/cyclophosphamide: Preliminary report of a phase III, randomized trial in stages III-IV, suboptimal ovarian cancer. Proc Am Soc Clin Oncol 8:151, 1989 (abstr)
21. Markman M, Reichman B, Hakes T, et al: Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer. Gynecol Oncol 50:100-104, 1993
22. Tosetti F, Rocco M, Fulco RA, et al: Serial determination of platinum, protein content and free sulfhydryl levels in plasma of patients treated with cisplatin or carboplatin. Anticancer Res 8:381-386, 1988
23. Kahan BD, Grevel J: Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy. Transplantation 46:631-644, 1988
24. Elferink F, van der Vijgh WJF, Klein IL, et al: Pharmacokinetics of carboplatin after intraperitoneal administration. Cancer Chemother Pharmacol 21:57-60, 1988
25. DeGregorio MW, Lum BL, Holleran WM, et al: Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase 1 study of the Northern California Oncology Group. Cancer Chemother Pharmacol 18:235-238, 1986
26. Cockburn I: Cyclosporin-A: A clinical evaluation of drug interactions. Transplant Proc 18:50-55, 1986 (suppl 5)
27. Critical issues in cyclosporine monitoring: Report of the Task Force on Cyclosporine Monitoring. Clin Chem 33:1269-1288, 1987
28. Chambers JT, Chambers SK, Schwartz PE: Correlation between measured creatinine clearance and calculated creatinine in ovarian cancer patients. Gynecol Oncol 36:66-68, 1990
29. Paul K, Harding MW, Marks WH, et al: Cyclophilin binding: A more accurate measure of cyclosporine immunosuppressive activity after renal transplantation. Transplant Proc 23:974-975, 1991
30. Lorber MI, Paul K, Harding MW, et al: Cyclophilin binding: A receptor-mediated approach to monitoring cyclosporine immuno-suppressive activity following organ transplantation. Transplant Proc 22:1240-1244, 1990
31. Chambers JT, Chambers SK, Voynick IM, et al: Neoadjuvant chemotherapy for stage X ovarian cancer. Gynecol Oncol 37:327-331, 1990
32. Markman M, Hoskins W: Responses to salvage chemotherapy in ovarian cancer: A critical need for precise definitions of the treated population. J Clin Oncol 10:513-514, 1992 (editorial)
33. Chambers JT, Chambers SK, Kohorn EI, et al: Uterine papillary serous carcinoma treated with intraperitoneal cisplatin and intravenous doxorubicin and cyclophosphamide. Gynecol Oncol 60:438-442, 1996
34. Markman M, Rowinsky E, Hakes T, et al: Phase I trial of intraperitoneal Taxol: A Gynecologic Oncology Group study. J Clin Oncol 10:1485-1491, 1992
35. Markman M, Rothman R, Hakes T, et al: Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9:389-393, 1991
36. Markman M, Reichman B, Hakes T, et al: Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: Influence of a prior response to intravenous cisplatin. J Clin Oncol 9:1801-1805, 1991
37. Alberts DS, Liu PY, Hannigan EV, et al: Phase II study of intraperitoneal (IP) cisplatin (CDPP)/intravenous (IV) cyclophosphamide (CPA) vs CDDP/IVCPA in patients with optimal disease stage III ovarian cancer: A SWOG-GOG-ECOG intergroup study (INT 0051). Proc Am Soc Clin Oncol 14:273, 1995 (abstr 760)